 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.114.291 |
| Chemical and physical data | |
| Formula | C22H25N3O2 |
| Molar mass | 363.461 g·mol−1 |
| 3D model ( JSmol) | |
| |
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems [1] [2] but not in human hearts. [3] [4] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted. [5]
See also
References
- ^ "formularyjournal.modernmedicine.com". Archived from the original on 2012-03-04.
- ^ Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi: 10.1159/000028179. PMID 9467185. S2CID 46848815.
- ^ Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ (December 1998). "The role of third-generation beta-blocking agents in chronic heart failure". Clinical Cardiology. 21 (S1): I3–I13. doi: 10.1002/clc.4960211303. PMC 6656140. PMID 9853189.
- ^ Hershberger RE, Wynn JR, Sundberg L, Bristow MR (June 1990). "Mechanism of Action of Bucindolol in Human Ventricular Myocardium". Journal of Cardiovascular Pharmacology. 15 (6): 959–967. doi: 10.1097/00005344-199006000-00014. PMID 1694919.
- ^ "FDA rejects bucindolol and questions trial integrity « CardioBrief". 2 June 2009.
 | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |